Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VERVE-102 versus placebo in adults with or at high risk for atherosclerotic cardiovascular disease requiring additional LDL-C lowering
jRCT2033260630Phase 2Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of VERVE-102 in atherosclerotic disease and hypercholesterolemia (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent change from baseline in LDL-C. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
VERVE-102
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on jRCT2033260630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260630.